(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/207550 A1

(51) International Patent Classification:
C07D 495/04 (2006.01) *A61K 31/519* (2006.01)
C07D 519/00 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/US2021/026477

(22) International Filing Date:
08 April 2021 (08.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/007,327	08 April 2020 (08.04.2020)	US
63/043,920	25 June 2020 (25.06.2020)	US
63/072,873	31 August 2020 (31.08.2020)	US
63/126,493	16 December 2020 (16.12.2020)	US

(71) Applicant: **REMIX THERAPEUTICS INC.** [US/US]; One Kendall Square, Building 600, 4th Floor, Cambridge, MA 02139 (US).

(72) Inventors: **REYNOLDS, Dominic**; One Kendall Square, Building 600, 4th Floor, Cambridge, MA 02139 (US). **LEGER, Serge**; One Kendall Square, Building 600, 4th Floor, Cambridge, MA 02139 (US). **SEILER, Michael, W.**; One Kendall Square, Building 600, 4th Floor, Cambridge, MA 02139 (US). **AGRAWAL, Anant, A.**; One Kendall Square, Building 600, 4th Floor, Cambridge, MA 02139 (US). **VAILLANCOURT, Frederic**; One Kendall Square, Building 600, 4th Floor, Cambridge, MA 02139 (US). **SMITH, Peter**; One Kendall Square, Building 600, 4th Floor, Cambridge, MA 02139 (US). **PRAJAPATI, Sudeep**; One Kendall Square, Building 600, 4th Floor, Cambridge, MA 02139 (US).

(74) Agent: **LU, David** et al.; Lando & Anastasi, LLP, 60 State Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2021/207550 A1

(54) Title: COMPOUNDS AND METHODS FOR MODULATING SPLICING

(57) Abstract: The present disclosure features compounds and related compositions that, *inter alia*, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.